Have Questions About Psilocybin-Assisted Therapy? Here are the Terms You Need to Know
Last reviewed and updated: July 5, 2026
Key Takeaways
| New vocabulary | The psychedelic therapy field has developed significant new terminology since 2022 — healing center, natural medicine facilitator, rolling NDA, neuroplasticity window, and precision psychedelics are now common terms. |
| Oregon framework terms | In Oregon, the key terms are: “service center” (the licensed facility), “psilocybin facilitator” (the licensed guide), “preparation session” (required pre-experience meeting), and “integration session” (required post-experience follow-up). |
| Colorado terms | Colorado uses “healing center” (vs. “service center”) and “natural medicine facilitator” — and covers a broader substance list under “natural medicine.” |
| Regulatory glossary | Key regulatory terms include: NDA (New Drug Application), rolling NDA (Compass Pathways’ submission approach), Breakthrough Therapy Designation, and Complete Response Letter (what MDMA received in 2024 = rejection). |
| Neuroplasticity window | Research shows elevated neuroplasticity in the 24-72 hours post-session — now commonly called the “neuroplasticity window” or “afterglow period” — when integration therapy is most impactful. |
Magic mushrooms are everywhere these days. Whether it’s titans of industry, athletes or moms, everyone is using psilocybin mushrooms to treat everything from depression and anxiety to PTSD and beyond.
The number of psilocbyin retreats around the globe has exploded and Oregon’s psilocybin retreat centers are just starting to open. In short, more and more people are seeking this new alternative mental health treatment. So what are some of the terms you need to know to help you navigate this new world? Here are some of the most important.
A Glossary of Psilocybin-Assisted Therapy Terms
5HT2A: The receptor in the brain primarily effected by psilocybin.
Aftercare: This is the phase following the psilocybin therapy session. It’s critical because the effects of psilocybin can be profound and disorienting. Aftercare includes activities and practices that help individuals process their experiences, such as journaling, counseling, and group sharing sessions.
Afterglow: A feeling of well-being after a medicine session.
Attachment style: Avoidant, disorganized, preoccupied–how clients relate to others is an important consideration in therapy. Therapy centers on the relationship of the client with the provider. The therapist should know the attachment style of the client–and their own attachment style.
Compass Pathways: The company bringing psilocybin-assisted therapy through the FDA approval process.
Contraindications: These are specific health conditions where psilocybin should not be used because it may be harmful. Healthcare providers may advise individuals with a personal or family history of psychotic disorders against psilocybin therapy. They may also caution those with certain medical conditions.
Container: The setting or structure in which psilocybin-assisted therapy takes place. Includes the physical space and the emotional or psychological support.
Default Mode Network: The pattern of brain activity at work during most of daily life. Psilocybin dampens this network, creating new pathways of mental activity.
Dosage: The dose can significantly influence the nature of the psilocybin experience. Healthcare providers carefully calibrate dosages according to the individual’s body weight, sensitivity to the substance, and therapeutic objectives.
Empathetic Abiding Presence: How therapists are instructed to act during a session. Offering a steady and reassuring demeanor–without directing or judging.
Entheogen: Due to their traditional use in spiritual and religious ceremonies to engender mystical or transcendental experiences, people often call psilocybin an entheogens. The word means “generating the divine within,” from the Greek words en (in) theo (divine) and gen (generate).
Eyeshades: Light-blockers clients wear so they can “go inward” and feel their feelings, without being distracted.
Facilitator: Facilitator is an umbrella word for anyone who cares for someone on psychedelics or leads a psychedelic session or ceremony. A facilitator guides and supports individuals through psychedelic experiences. Facilitators ensure the session’s safety and maintain a secure environment for the participant throughout the process.
Indication: The reason behind prescribing psilocybin-assisted therapy. Right now, Compass Pathways is looking into psilocybin-assisted therapy for depression.
Integration: Integration is a cornerstone of psilocybin therapy, where participants work to understand and apply the insights from their psychedelic experience in their everyday life. It often involves structured conversations with therapists or peers.
Intention Setting: Guides often help participants set clear intentions before a psilocybin session, which can shape the experience and focus the participants’ minds on specific areas of personal growth or healing.
Legality: The legal context for psilocybin varies by country and, in some places, by state or region. Where it’s legal, there are often strict regulations around its therapeutic use.
Microdosing: People often practice taking low doses of psilocybin. These doses are insufficient for a full psychedelic effect but reportedly boost creativity, energy, and emotional balance.
Meaning-making: After a session, it’s helpful for the client to frame or interpret their experience in a way that speaks to them. For example: “I saw bright warm visuals” can change to “there’s light at the end of the tunnel of my sadness.” The therapist should help the client make their own meaning–not interpret things for them.
Music: Plays an important role. Still and peaceful music can reassure and calm a client, especially during the come-up and come-down. On the other hand, evocative, dissonant or tense music can be provoking and heightening, steering the client toward a peak experience.
Noetic: A feeling that important truths have been revealed by psychedelics.
Parts work: A type of therapy, growing more popular among psilocybin-assisted therapists. A person is said to have different “parts” of themselves, like an “inner child,” “inner critic,” or “inner healer.” The therapist works with each part to bring healing.
Peak Experience: The most intense part of a journey, often full of colorful visuals and strong emotions.
Preparation Session: Before experiencing psilocybin therapy, individuals usually have one or more sessions with a facilitator to build rapport, establish trust, and discuss the process and any potential fears or concerns.
Psilocybin: Psilocybin is the psychoactive substance found in certain mushrooms. It can induce profound changes in perception, emotion, and cognition during a psychedelic experience.
Psychotherapy: Psychotherapists may use psychotherapy in conjunction with the psychedelic experience during psilocybin therapy. This helps individuals process and make sense of their experiences.
Psycholytic dose: A medium dose that doesn’t incapacitate; it “loosens” the psyche;–freeing the client to reach into their subconscious, while still being able to talk and do therapy.
Retreat: Structured programs, often set in serene, natural environments, provide participants with group psilocybin therapy sessions that frequently include a ceremonial aspect.
Screening: Potential participants undergo a screening process to ensure that psilocybin therapy is safe and appropriate for them. These screening processes take into account medical history, mental health, and other personal factors.
Self-care: How the therapist takes care of themselves during a medicine sessions, which can last from 6 to 12 hours. Includes taking breaks, eating snacks, drinking water, and stretching.
Set: This term refers to the internal attitudes, expectations, and psychological readiness of an individual prior to a psilocybin session, which can significantly affect the experience.
Setting: This involves the external environment where the psilocybin session takes place. A supportive, comfortable, and safe setting is vital for a positive therapeutic outcome.
Sitter: This is someone who stays with the participant during the psilocybin experience, offering support as needed.
Therapeutic Alliance: The relationship of trust and understanding between the therapist and client that is essential for effective therapy. A strong alliance can help clients feel safe enough to explore difficult psychological territory.
Transpersonal: Extending beyond the personal, especially in regard to the mystical or supernatural.
Trauma: A negative experience that damages a person’s ability to thrive in the world.
Trip: Although the term is common in recreational contexts to describe a psychedelic experience, therapists generally avoid it in clinical settings due to its informal and recreational connotations.
Tryptamine: The class of drug to which psilocybin belongs, a category that includes DMT and 5-Meo-DMT.
Unconditional Positive Regard: How therapists should treat their clients. Seeing them as human, valuable and worthwhile, regardless of their situation, values or beliefs.
Vulnerability Factors: These are individual traits or current life circumstances that might increase the likelihood of a negative reaction to psilocybin, such as acute life stressors or a history of trauma.
2026 Update
Psilocybin-assisted therapy has developed its own vocabulary rapidly since Oregon launched the first licensed program in 2022. The terms “healing center,” “natural medicine facilitator,” “neuroplasticity window,” and “precision psychedelics” barely existed three years ago. On the regulatory side, terms like “rolling NDA,” “Breakthrough Therapy Designation,” and “Complete Response Letter” have become essential for understanding the approval landscape — the last of these is what MDMA-assisted therapy received in August 2024 when the FDA rejected it. Understanding these terms is now necessary for anyone trying to navigate the difference between what’s legal, what’s in trials, and what’s coming next.
The “neuroplasticity window” — the 24-72 hour period of elevated neuroplasticity following a psilocybin session — has become a central concept in integration-focused care. Research shows that this window represents the peak opportunity for therapeutic work: the brain is more plastic, new connections are easier to form, and the insights from the session are most accessible. Oregon’s requirement for an integration session builds this concept into law. “Precision psychedelics” is an emerging term describing the effort to match specific compounds to specific conditions — psilocybin for existential distress and depression, ketamine for acute suicidal ideation, MDMA for relational trauma, ibogaine for addiction — rather than treating all psychedelics as interchangeable.
Frequently Asked Questions
- What is a “healing center” vs. a “service center”?
- Both refer to licensed facilities where supervised psychedelic experiences take place — but they use different terminology. Oregon uses “psilocybin service center.” Colorado uses “natural medicine healing center” (or “healing center”). The functional difference matters: Colorado’s healing centers can offer a broader range of substances (psilocybin, DMT, ibogaine, mescaline, muscimol) under its Natural Medicine Health Act, while Oregon’s service centers are currently psilocybin-only.
- What is the “neuroplasticity window” after psilocybin?
- Research indicates that neuroplasticity — the brain’s capacity to form new connections and reorganize — is elevated for approximately 24-72 hours following a psilocybin session. This period, sometimes called the “afterglow” or “neuroplasticity window,” is when the insights and emotional processing from the session are most accessible and when therapeutic work (integration therapy, journaling, meaningful conversations) has the greatest impact on long-lasting change.
- What does “rolling NDA” mean in psychedelic medicine?
- A “rolling NDA” (New Drug Application) is a regulatory submission strategy where a company submits completed sections of a drug approval application to the FDA as they’re finished, rather than waiting until the entire application is complete. Compass Pathways submitted a rolling NDA for its psilocybin compound (COMP360) in 2025. This approach can speed the review timeline by allowing the FDA to begin evaluating early sections while research continues.
- What is “precision psychedelics”?
- Precision psychedelics is an emerging framework that calls for matching specific psychedelic compounds to specific patient conditions and biological profiles — rather than treating all psychedelics as interchangeable. Under this model: ketamine is preferred for acute suicidal ideation (fast onset); psilocybin for existential distress and treatment-resistant depression (lasting neuroplasticity); MDMA for relational and complex trauma (empathogen effects); ibogaine for addiction (multi-receptor anti-addiction action). The approach is analogous to precision medicine in oncology.
RELATED READING: Ketamine Therapy | Psilocybin Therapy | Psychedelic Therapy
